Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

NCT01484873 on ClinicalTrials.gov · last registry update 2017-03-03

A small phase 2 — 10 participants, against a typical 110. The sponsor logged completion for March 2015. Primary outcome, as filed: Body Weight (kg). exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Vanderbilt University Medical Center
Sponsor type: Other
Enrollment: 10
Started: 2012-06
Primary completion: 2015-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Body Weight (kg)

Conditions studied

Obesity · Overweight · Craniopharyngioma

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.